CWG
C WorldWide Group Portfolio holdings
AUM
$7.38B
This Quarter Return
+7.82%
1 Year Return
+18.35%
3 Year Return
+71.53%
5 Year Return
+105.42%
10 Year Return
+360.65%
AUM
$7.79B
AUM Growth
+$7.79B
(+8%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
1.63%
Top 10 Holdings %
Top 10 Hldgs %
71.8%
Holding
138
New
7
Increased
44
Reduced
53
Closed
7
Top Buys
| 1 |
Exxon Mobil
XOM
|
$363M |
| 2 |
Procter & Gamble
PG
|
$151M |
| 3 |
Coca-Cola
KO
|
$22.9M |
| 4 |
AMRN
Amarin Corp
AMRN
|
$11.1M |
| 5 |
HDFC Bank
HDB
|
$9.04M |
Top Sells
| 1 |
Philip Morris
PM
|
$216M |
| 2 |
Citigroup
C
|
$120M |
| 3 |
Visa
V
|
$67.4M |
| 4 |
DexCom
DXCM
|
$6.31M |
| 5 |
KTWO
K2M Group Holdings, Inc
KTWO
|
$5.35M |
Sector Composition
| 1 | Financials | 26.45% |
| 2 | Consumer Discretionary | 18.43% |
| 3 | Healthcare | 14.45% |
| 4 | Communication Services | 13.53% |
| 5 | Consumer Staples | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merck
MRK
$210B
| $23.4M | 0.3% | 329,955 | – | – |
|
27
Amgen
AMGN
$155B
| $23M | 0.29% | 110,716 | – | – |
|
28
Biogen
BIIB
$19.4B
| $20.9M | 0.27% | 59,070 +10,484 | +22% | +$3.7M |
|
29
Gilead Sciences
GILD
$140B
| $16.5M | 0.21% | 213,104 -32,879 | -13% | -$2.54M |
|
30
Edwards Lifesciences
EW
$47.8B
| $16.1M | 0.21% | 92,393 | – | – |
|
31
Vertex Pharmaceuticals
VRTX
$100B
| $14.5M | 0.19% | 75,343 +10,813 | +17% | +$2.08M |
|
|
AGN
32
DELISTED
Allergan plc
AGN
| $14.5M | 0.19% | 75,890 -9,211 | -11% | -$1.75M |
|
|
SHPG
33
DELISTED
Shire pic
SHPG
| $14.3M | 0.18% | 78,678 | – | – |
|
34
Boston Scientific
BSX
$156B
| $14.1M | 0.18% | 367,194 | – | – |
|
35
Becton Dickinson
BDX
$55.3B
| $13.8M | 0.18% | 52,955 | – | – |
|
36
Centene
CNC
$14.3B
| $13.6M | 0.17% | 93,653 | – | – |
|
37
HCA Healthcare
HCA
$94.5B
| $12.9M | 0.17% | 92,727 +13,192 | +17% | +$1.84M |
|
38
AbbVie
ABBV
$372B
| $11.9M | 0.15% | 125,780 -17,491 | -12% | -$1.65M |
|
|
CELG
39
DELISTED
Celgene Corp
CELG
| $11.3M | 0.15% | 126,797 +3,727 | +3% | +$334K |
|
|
AMRN
40
Amarin Corp
AMRN
$311M
| $11.1M | 0.14% | +680,000 | New | +$11.1M |
|
41
Eli Lilly
LLY
$657B
| $9.86M | 0.13% | 91,848 | – | – |
|
|
ESRX
42
DELISTED
Express Scripts Holding Company
ESRX
| $9.59M | 0.12% | 100,939 -18,665 | -16% | -$1.77M |
|
43
Viatris
VTRS
$12.3B
| $9.42M | 0.12% | 257,473 -73,195 | -22% | -$2.68M |
|
|
ALXN
44
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.15M | 0.12% | 65,847 -9,727 | -13% | -$1.35M |
|
45
NovoCure
NVCR
$1.38B
| $8.64M | 0.11% | 164,953 -48,200 | -23% | -$2.53M |
|
46
Jazz Pharmaceuticals
JAZZ
$7.75B
| $8.4M | 0.11% | 49,935 +343 | +0.7% | +$57.7K |
|
47
Cigna
CI
$80.3B
| $7.65M | 0.1% | 36,723 | – | – |
|
48
Sarepta Therapeutics
SRPT
$1.78B
| $7.6M | 0.1% | 47,046 -22,381 | -32% | -$3.61M |
|
49
Bristol-Myers Squibb
BMY
$96B
| $7.46M | 0.1% | 120,199 | – | – |
|
50
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.32M | 0.09% | 75,431 +18,919 | +33% | +$1.83M |
|